US 12091675
Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
granted A61KA61K38/37A61K48/0075
Quick answer
US patent 12091675 (Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression) held by Takeda Pharmaceutical Company Limited expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K38/37, A61K48/0075, A61K48/0083